Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p<0.0001 / p=0.0035)
- Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels
- Detailed results presented today at the Seventeenth European Meeting on Hypertension in Milan, Italy

SCHLIEREN (Zurich), Switzerland and MILAN, Italy, June 17, 2007 - Cytos Biotechnology AG (SWX:CYTN) presented today new clinical data on its hypertension vaccine CYT006-AngQb at the Seventeenth European Meeting on Hypertension in Milan, Italy. The vaccine candidate was tested in a placebocontrolled, double-blind phase IIa clinical trial in 72 patients with mild to moderate hypertension.

On January 26, 2007, Cytos Biotechnology reported top-line data from this study, which showed that the 300 ?g dose of the vaccine was safe, very well tolerated and efficacious in lowering day-time ambulatory blood pressure. The new data presented today show a particularly strong efficacy of the vaccine in early morning hours, a critical time period when serious cardiovascular events frequently occur. The graph below shows the mean ambulatory blood pressure during the 24-hour measurement period 14 weeks after the first injection of the vaccine or of placebo. The early morning rise of blood pressure starting at 5 am was significantly suppressed by the vaccine, leading at 8 am to a change from baseline of the blood pressure of - 25 / - 13 mm Hg compared to placebo (SBP / DBP, p<0.0001 / p=0.0035).


*SEE ATTACHMENT FOR FIGURE*

The strong suppression of the early morning rise of blood pressure was associated with an exceptionally low increase in plasma renin concentration (PRC) from a mean renin concentration of 5.1 pg/ml at baseline to 6.3 pg/ml at week 14 (p=0.02). Inhibition of the renin-angiotensin system by small molecule drugs is known to induce a reactive rise of the plasma renin concentrati
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:7/29/2014)... LONDON , July 29, 2014 ... 2014 Global Frost & Sullivan Best Practices Award ... solution is a cloud-based platform that connects digital ... - such as providers, pharmaceutical companies, prevention and ... electronics. Each year, Frost & ...
(Date:7/29/2014)... , July 29, 2014   Health 2.0 ... a keynote alongside visionary physicians Eric Topol , ... at the Health 2.0 8th Annual Fall Conference ... This year, Health 2.0 is set to host ... of the larger session on Consumer Tech & Wearables: ...
(Date:7/28/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... webcast to discuss financial results for the second quarter of ... 2014 at 4:30 p.m. ET. Conference call ... 2014 Time: 4:30 PM ET Listen via Internet: http://ir.pharmacyclics.com/events.cfm ... A webcast replay will be available on the Pharmacyclics website ...
Breaking Medicine Technology:Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2
... Inc. (OTC Bulletin Board: WGBS ), a leading developer ... an overview of the company at the 13th annual BIO CEO ... Hotel, Tuesday, February 15, 2011 at 11:30 a.m. Eastern time.  The ... may be accessed at www.wafergen.com . The BIO ...
... Caliper Life Sciences, Inc. (Nasdaq: CALP ) ... protocols on its Sciclone® NGS Workstation for Illumina,s TruSeq™ ... In addition to the automation protocols for TruSeq kits, ... library preparation kits, as well as for Agilent,s SureSelect™ ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2Caliper Life Sciences Announces Availability of Automated TruSeq™ Next Generation Sequencing Protocols 2
(Date:7/29/2014)... News) -- Decorative contact lenses may seem like a ... cause serious eye damage. Decorative contacts should be ... the U.S. Food and Drug Administration (FDA). It,s important ... for these lenses and buy them from a trustworthy ... about the potential health risks associated with decorative contact ...
(Date:7/29/2014)... 29, 2014 July 29, 2014 – Silverado, ... is proud to announce that it is a Bronze winner ... video segments; Silverado Through a Child's Eye and ... In Silverado Through a Child's Eye , seven-year-old Mia ... at Silverado Beverly Place, a memory care community in Los ...
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 According ... marijuana in both the recreational and the medicinal sectors ... As legalized marijuana becomes more accepted in mainstream culture, ... drug aside from the traditional and more dangerous forms ... products are becoming quite the trend in legalized states ...
(Date:7/29/2014)... Boca Raton, FL (PRWEB) July 29, 2014 ... will officially launch its products in the UK in September. ... company’s products will be available Sept. 7 on Amazon.co.uk. , ... has been growing and we are truly looking forward to ... Amazon.co.uk will include OZ Naturals bestselling Vitamin C serum ...
(Date:7/29/2014)... July 29, 2014 PhyMed Healthcare ... anesthesia, pain management and critical care, has named Ryan ... to PhyMed in May 2013 as our vice president ... part of our organization and leadership team,” says Dr. ... is a cornerstone of our strategic vision and Ryan ...
Breaking Medicine News(10 mins):Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Marijuana Edibles Sales Show Growth in Market 2Health News:OZ Naturals to Launch Its Products in the UK 2Health News:PhyMed Names Dorr to Chief Information Office Post 2
... Tata Industries Ltd today said it has acquired a ... indigene Pharma Inc// , for an undisclosed amount. ... in the business of both prescription and consumer healthcare ... Indigene, Tata Group Chairman Ratan Tata said the group ...
... at rest the "controversy" over the number of HIV/AIDS patients ... its figures of 5.2 million// patients was in consonance with ... figures on HIV/AIDS patients are for the age group of ... prone to the disease," Sujata Rao, Director-General, NACO told reporters ...
... in Malaysia Putrajaya Malaysia, The Malaysian government proposes ... HIV/AIDS// sufferers who falsify information about their condition to ... Infectious Diseases Act 1988 would be amended to make ... Razak said. ,"There have been several cases ...
... Health Department in June, officials had pointed out certain ... had revealed certain lapses in the candy production area, ... entry points for rodents. Despite necessitating immediate remedies by ... had done precious little to correct the irregularities., ...
... innovation to examine one’s heart.Usually an angiogram is performed where ... the groin or forearm and advanced through the arterial system ... This would take a few hours but for a patient ... to six hours. But this new 64-slice CT scanner which ...
... receives cochlear implants better will be his or her spoken language ... 3? year-old child, born as deaf but used cochlear implants, able ... make use of it. ,In contrast, a child of ... made more sophisticated statements: ‘OK, now the people goes to stand ...
Cached Medicine News:Health News:Earlier the Cochlear Implants Used Better the Speech 2Health News:Earlier the Cochlear Implants Used Better the Speech 3
... eyewear and sunwear, inspired by ... personal style, with long lasting ... the collection include sophistication, elegance ... offer clean modern shapes, classic ...
... designs with children in mind, making eyewear ... stay-put cable temples. Its not surprising that ... as the best selling childrens collection from ... popular is its ability to keep pace ...
... The Calvin Klein Collection. Provocatively inspired ... - a bold outlook. Innovative structure: ... Modern technology enhances modern design. Technological ... and enhance the face., ,The Calvin ...
Inquire...
Medicine Products: